Dopamine and Antioxidant Grape Seed Extract loaded chitosan nanoparticles: A preliminary in vitro characterization

Stefano Bellucci; Giuseppe Fracchiolla; Alessandra Pannunzio; Antonello Caponio; Daniela Donghia; Filomena Corbo; Loredana Capobianco; Antonella Muscella; Daniela Erminia Manno; Erika Stefàno; Santo Marsigliante; Adriana Trapani

doi:10.59400/nmm.v3i1.40

Stefano Bellucci Istituto Nazionale di Fisica Nucleare-Laboratori Nazionali di Frascati
Giuseppe Fracchiolla University of Bari “Aldo Moro”
Alessandra Pannunzio University of Bari “Aldo Moro”
Antonello Caponio University of Bari “Aldo Moro”
Daniela Donghia University of Bari “Aldo Moro”
Filomena Corbo University of Bari “Aldo Moro”
Loredana Capobianco University of Salento
Antonella Muscella University of Salento
Daniela Erminia Manno University of Salento
Erika Stefàno University of Salento
Santo Marsigliante University of Salento
Adriana Trapani University of Bari “Aldo Moro”

Ariticle ID: 40

265 Views, 191 PDF Downloads

DOI: https://doi.org/10.59400/nmm.v3i1.40

Keywords: dopamine, chitosan nanoparticles, radical oxygen species, SHSY-5Y cell line, OxyBlot analysis

Abstract

Neuronal cell model line SHSY-5Y is extensively adopted when in vitro investigations are related to Parkinson disease (PD) application. Herein, chitosan nanoparticles (CS NPs) were formulated for the co-administration of dopamine (DA) and Grape Seed Extract (GSE) with the aim to gain insight into the interactions occurring between SHSY-5Y and NPs. Following the ionic gelation technique, the mean particle size of the NPs resulted in the range 310–330 nm and the zeta measurements were in the range +16.4 – +35.5 mV. The presence of CS chains on the surface suggested by positive zeta values was also confirmed by FT-IR analysis, whereas storage stability studies upon different temperatures evidenced that, although aggregation occurred, DA autoxidation was prevented because no black suspensions were detected over the time, irrespectively of the temperature assayed. From a biological viewpoint, release studies of CS NPs loaded with DA and GSE showed that in SHSY-5Y cell lines DA accumulation was time-dependent, irrespectively of the presence of GSE. Furthermore, ROS levels and carbonylated proteins both decreased in SHSY-5Y cell line once NPs administering both DA and GSE were incubated, suggesting a significative reduction of oxidative stress which plays a significative role for PD development.

References

[1] Trapani A, De Giglio E, Cafagna D, et al. Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery. International Journal of Pharmaceutics 2011; 419(1-2): 296–307. doi: 10.1016/j.ijpharm.2011.07.036.

[2] Aktas Y, Andrieux K, Alonso MJ, et al. Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor. International Journal of Pharmaceutics 2005; 298(2): 378–383. doi: 10.1016/j.ijpharm.2005.03.027.

[3] Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carrier. Journal of Applied Polymer Science 1997; 63(1): 125–132. doi: 10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4.

[4] Tobio M, Sánchez A, Vila A, et al. The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloids and Surfaces B: Biointerfaces 2000; 18(3-4): 315–323. doi: 10.1016/S0927-7765(99)00157-5.

[5] Di Gioia S, Trapani A, Mandracchia D, et al. Intranasal delivery of dopamine to the striatum using glycol chitosan/sulfobutylether-β-cy- clodextrin based nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics 2015; 94: 180–193. doi: 10.1016/j.ejpb.2015.05.019.

[6] Conese M, Cassano R, Gavini E, et al. Harnessing stem cells and neurotrophic factors with novel technologies in the treatment of Parkinson’s disease. Current Stem Cell Research & Therapy 2019; 14(7): 549–569. doi: 10.2174/1574888X14666190301150210.

[7] Rocha EM, De Miranda B, Sanders LH. Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson’s disease. Neurobiology of Disease 2018; 109(Pt B): 249–257. doi: 10.1016/j.nbd.2017.04.004.

[8] Zemljič LF, Plohl O, Vesel A, et al. Physicochemical characterization of packaging foils coated by chitosan and polyphenols colloidal formulations. International Journal of Molecular Sciences 2020; 21(2): 495. doi: 10.3390/ijms21020495.

[9] Fahmy HM, Khadrawy YA, Abd-El Daim TM, et al. Thymoquinone-encapsulated chitosan nanoparticles coated with polysorbate 80 as a novel treatment agent in a reserpine-induced depression animal model. Physiology & Behavior 2020; 222: 112934. doi: 10.1016/j.physbeh.2020.112934.

[10] Md S, Alhakamy NA, Aldawsari HM, Asfour HZ. Neuroprotective and antioxidant effect of naringenin-loaded nanoparticles for nose-to-brain delivery. Brain Sciences 2019; 9(10): 275. doi: 10.3390/brainsci9100275.

[11] Ahlawat J, Neupane R, Deemer E, et al. Chitosan-ellagic acid nanohybrid for mitigating rotenone-induced oxidative stress. ACS Applied Materials & Interfaces 2020; 12(16): 18964–18977. doi: 10.1021/acsami.9b21215.

[12] Felice F, Zambito Y, Belardinelli E, et al. Delivery of natural polyphenols by polymeric nanoparticles improves the resistance of endothelial progenitor cells to oxidative stress. European Journal of Pharmaceutical Sciences 2013; 50(3-4): 393–399. doi: 10.1016/j.ejps.2013.08.008.

[13] Trapani A, Guerra L, Corbo F, et al. Cyto/Biocompatibility of dopamine combined with the antioxidant grape seed-derived polyphenol compounds in solid lipid nanoparticles. Molecules 2021; 26(4): 916. doi: 10.3390/molecules26040916.

[14] De Giglio E, Trapani A, Cafagna D, et al. Dopamine-loaded chitosan nanoparticles: Formulation and analytical characterization. Analytical and Bioanalytical Chemistry 2011; 400: 1997–2002. doi: 10.1007/s00216-011-4962-y.

[15] Castellani S, Trapani A, Spagnoletta A, et al. Nanoparticle delivery of grape seed-derived proanthocyanidins to airway epithelial cells dampens oxidative stress and inflammation. Journal of Translational Medicine 2018; 16(1): 140. doi: 10.1186/s12967-018-1509-4.

[16] Trapani A, Esteban MÁ, Curci F, et al. Solid lipid nanoparticles administering antioxidant grape seed-derived polyphenol compounds: A potential application in aquaculture. Molecules 2022; 27(2): 344. doi: 10.3390/molecules27020344.

[17] Trapani A, De Giglio E, Cometa S, et al. Dopamine-loaded lipid based nanocarriers for intranasal administration of the neurotransmitter: A comparative study. European Journal of Pharmaceutics and Biopharmaceutics 2021; 167: 189–200. doi: 10.1016/j.ejpb.2021.07.015.

[18] Cometa S, Bonifacio MA, Trapani G, et al. In vitro investigations on dopamine loaded Solid Lipid Nanoparticles. Journal of Pharmaceutical and Biomedical Analysis 2020; 185: 113257. doi: 10.1016/j.jpba.2020.113257.

[19] Carbone C, Campisi A, Manno D, et al. The critical role of didodecyldimethylammonium bromide on physico-chemical, technological and biological properties of NLC. Colloids and Surfaces B: Biointerfaces 2014; 121: 1–10. doi: 10.1016/j.colsurfb.2014.05.024.

[20] Mandracchia D, Trapani A, Perteghella S, et al. pH-sensitive inulin-based nanomicelles for intestinal site-specific and controlled release of celecoxib. Carbohydrate Polymers 2018; 181: 570–578. doi: 10.1016/j.carbpol.2017.11.110.

[21] Di Gioia S, Trapani A, Cassano R, et al. Nose-to-brain delivery: A comparative study between carboxymethyl chitosan based conjugates of dopamine. International Journal of Pharmaceutics 2021; 599: 120453. doi: 10.1016/j.ijpharm.2021.120453.

[22] Trapani A, De Laurentis N, Armenise D, et al. Enhanced solubility and antibacterial activity of lipophilic fluoro-substituted N-benzoyl-2-aminobenzothiazoles by complexation with β-cyclodextrins. International Journal of Pharmaceutics 2016; 497(1-2): 18–22. doi: 10.1016/j.ijpharm.2015.11.024.

[23] Trapani A, Catalano A, Carocci A, et al. Effect of Methyl-β-Cyclodextrin on the antimicrobial activity of a new series of poorly water-soluble benzothiazoles. Carbohydrate Polymers 2019; 2017: 720–728. doi: 10.1016/j.carbpol.2018.12.016.

[24] Oliveira HR, Verlengia R, Carvalho CRO, et al. Pancreatic beta-cells express phagocyte-like NAD(P)H oxidase. Diabetes 2003; 52(6): 1457–1463. doi: 10.2337/diabetes.52.6.1457.

[25] Wang SF, Yen JC, Yin PH, et al. Involvement of oxidative stress-activated JNK signaling in the methamphetamine-induced cell death of human SH-SY5Y cells. Toxicology 2008; 246(2-3): 234–241. doi: 10.1016/j.tox.2008.01.020.

[26] Raj R, Wairkar S, Sridhar V, Gaud R. Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: Development, characterization and in vivo anti-Parkinson activity. International Journal of Biological Macromolecules 2018; 109: 27–35. doi: 10.1016/j.ijbiomac.2017.12.056.

[27] Mistry A, Glud SZ, Kjems J, et al. Effect of physicochemical properties on intranasal nanoparticle transit into murine olfactory epithelium. Journal of Drug Targeting 2009; 17(7): 543–552. doi: 10.1080/10611860903055470.

[28] Rukmangathen R, Yallamalli IM, Yalavarthi PR. Biopharmaceutical potential of selegiline loaded chitosan nanoparticles in the management of Parkinson’s disease. Current Drug Discovery Technologies 2019; 16(4): 417–425. doi: 10.2174/1570163815666180418144019.

[29] Santander-Ortega MJ, Jódar-Reyes AB, Csaba N, et al. Colloidal stability of pluronic F68-coated PLGA nanoparticles: A variety of stabilisation mechanisms. Journal of Colloid and Interface Science 2006; 302(2): 522–529. doi: 10.1016/j.jcis.2006.07.031.

[30] Hasegawa T, Matsuzaki M, Takeda A, et al. Increased dopamine and its metabolites in SH-SY5Y neuroblastoma cells that express tyrosinase. Journal of Neurochemistry 2003; 87(2): 470–475. doi: 10.1046/j.1471-4159.2003.02008.x.

[31] Chatzitaki AT, Jesus S, Karavasili C, et al. Chitosan-coated PLGA nanoparticles for the nasal delivery of ropinirole hydrochloride: In vitro and ex vivo evaluation of efficacy and safety. International Journal of Pharmaceutics 2020; 589: 119776. doi: 10.1016/j.ijpharm.2020.119776.

[32] Tian L, Zhou Z, Zhang Q, et al. Protective effect of (±) isoborneol against 6-OHDA-induced apoptosis in SH-SY5Y cells. Cellular Physiology and Biochemistry 2007; 20(6): 1019–1032. doi: 10.1159/000110682.

[33] Hara H, Hiramatsu H, Adachi T. Pyrroloquinoline quinone is a potent neuroprotective nutrient against 6-hydroxydopamine-induced neurotoxicity. Neurochemical Research 2007; 32: 489–495. doi: 10.1007/s11064-006-9257-x.

[34] Lee HJ. Noh YH, Lee DY, et al. Baicalein attenuates 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells. European Journal of Cell Biology 2005; 84(11): 897–905. doi: 10.1016/j.ejcb.2005.07.003.

[35] Foster KA, Galeffi F, Gerich FJ, et al. Optical and pharmacological tools to investigate the role of mitochondria during oxidative stress and neurodegeneration. Progress in Neurobiology 2006; 79(3): 136–171. doi: 10.1016/j.pneurobio.2006.07.001.

[36] Terracciano C, Nogalska A, Engel WK, et al. In inclusion-body myositis muscle fibers Parkinson-associated DJ-1 is increased and oxidized. Free Radical Biology & Medicine 2008; 45(6): 773–779. doi: 10.1016/j.freeradbiomed.2008.05.030.

[37] Fine JM, Forsberg AC, Stroebel BM, et al. Intranasal deferoxamine affects memory loss, oxidation, and the insulin pathway in the streptozotocin rat model of Alzheimer’s disease. Journal of the Neurological Sciences 2017; 380: 164–171. doi: 10.1016/j.jns.2017.07.028.

[38] Grünewald A, Voges L, Rakovic A, et al. Mutant Parkin impairs mitochondrial function and morphology in human fibroblasts. PLoS One 2010; 5(9): e12962. doi: 10.1371/journal.pone.0012962.